(Q38001955)

26 August 2017

title

Heparosan-derived heparan sulfate/heparin-like compounds: one kind of potential therapeutic agents (English)

1 reference

26 August 2017

Pingli Li

1

1 reference

26 August 2017

Juzheng Sheng

2

1 reference

26 August 2017

Yuhong Liu

3

1 reference

26 August 2017

Juan Li

4

1 reference

26 August 2017

Jian Liu

5

1 reference

26 August 2017

Fengshan Wang

6

1 reference

26 August 2017

publication date

11 April 2012

1 reference

Medicinal Research Reviews

26 August 2017

published in

1 reference

26 August 2017

volume

33

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

665-692

1 reference

The cell-based model of coagulation

26 August 2017

cites work

1 reference

The role of heparan sulphate proteoglycans in angiogenesis

21 January 2018

1 reference

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

21 January 2018

1 reference

The role of heparan sulphate in inflammation

21 January 2018

1 reference

Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier.

21 January 2018

1 reference

Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans

21 January 2018

1 reference

HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium

21 January 2018

1 reference

The signaling mechanisms of syndecan heparan sulfate proteoglycans

21 January 2018

1 reference

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

Enzymatic synthesis of glycosaminoglycan heparin

21 January 2018

1 reference

Evolution of glycosaminoglycans and their glycosyltransferases: Implications for the extracellular matrices of animals and the capsules of pathogenic bacteria

21 January 2018

1 reference

The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin

21 January 2018

1 reference

Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively

21 January 2018

1 reference

In vitro synthesis of heparosan using recombinant Pasteurella multocida heparosan synthase PmHS2.

21 January 2018

1 reference

Region 2 of the Escherichia coli K5 capsule gene cluster encoding proteins for the biosynthesis of the K5 polysaccharide

21 January 2018

1 reference

Determination of the substrate specificities of N-acetyl-d-glucosaminyltransferase

21 January 2018

1 reference

Identification of a distinct, cryptic heparosan synthase from Pasteurella multocida types A, D, and F.

21 January 2018

1 reference

Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases: monodisperse polymers and unnatural structures.

21 January 2018

1 reference

Heparan sulphate proteoglycans fine-tune mammalian physiology

21 January 2018

1 reference

Anticoagulant heparan sulfate: structural specificity and biosynthesis

21 January 2018

1 reference

Enzyme interactions in heparan sulfate biosynthesis: uronosyl 5-epimerase and 2-O-sulfotransferase interact in vivo

21 January 2018

1 reference

Design of biologically active heparan sulfate and heparin using an enzyme-based approach

21 January 2018

1 reference

Generation of "neoheparin" from E. coli K5 capsular polysaccharide.

21 January 2018

1 reference

Mechanisms of thrombus formation

21 January 2018

1 reference

Tissue factor coagulation pathway: a new therapeutic target in atherothrombosis

21 January 2018

1 reference

Tissue factor pathway inhibitor: structure, biology and involvement in disease

21 January 2018

1 reference

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

21 January 2018

1 reference

Enzymatic synthesis of antithrombin III–binding heparan sulfate pentasaccharide

21 January 2018

1 reference

Using an enzymatic combinatorial approach to identify anticoagulant heparan sulfate structures

21 January 2018

1 reference

Heparan sulphate N-sulphotransferase activity: reaction mechanism and substrate recognition

21 January 2018

1 reference

Enzymatic redesigning of biologically active heparan sulfate

21 January 2018

1 reference

Affinity, kinetic, and structural study of the interaction of 3-O-sulfotransferase isoform 1 with heparan sulfate

21 January 2018

1 reference

Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5.

21 January 2018

1 reference

Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.

21 January 2018

1 reference

The anti-inflammatory effects of heparin and related compounds

21 January 2018

1 reference

Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity.

21 January 2018

1 reference

Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins

21 January 2018

1 reference

N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo

21 January 2018

1 reference

Profiling heparin-chemokine interactions using synthetic tools

21 January 2018

1 reference

Defining the interleukin-8-binding domain of heparan sulfate

21 January 2018

1 reference

Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives

21 January 2018

1 reference

IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3.

21 January 2018

1 reference

Nonanticoagulant heparin reduces myocyte Na+ and Ca2+ loading during simulated ischemia and decreases reperfusion injury

21 January 2018

1 reference

Antagonistic effects of ultra-low-molecular-weight heparin against cerebral ischemia/reperfusion injury in rats

21 January 2018

1 reference

Ischemia-Reperfusion Injury : Pathophysiology and Clinical Implications

21 January 2018

1 reference

Mechanisms of heparin induced anti-cancer activity in experimental cancer models

21 January 2018

1 reference

The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients.

21 January 2018

1 reference

Cancer and venous thromboembolism.

21 January 2018

1 reference

Cancer, thrombosis and heparin-induced thrombocytopenia

21 January 2018

1 reference

Risk stratification for cancer-associated venous thromboembolism.

21 January 2018

1 reference

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review

21 January 2018

1 reference

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

21 January 2018

1 reference

Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery.

21 January 2018

1 reference

Tissue factor, thrombin, and cancer

21 January 2018

1 reference

Biological roles of fibroblast growth factor-2.

21 January 2018

1 reference

The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma

21 January 2018

1 reference

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium

21 January 2018

1 reference

Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.

21 January 2018

1 reference

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

21 January 2018

1 reference

Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response

21 January 2018

1 reference

Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells

21 January 2018

1 reference

Sulfated Derivatives of Escherichia coli K5 Polysaccharides as Modulators of Fibroblast Growth Factor Signaling

21 January 2018

1 reference

Interactions between heparan sulfate and proteins: the concept of specificity

21 January 2018

1 reference

Heparin structure and interactions with basic fibroblast growth factor

21 January 2018

1 reference

6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture

21 January 2018

1 reference

Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate.

21 January 2018

1 reference

Role of heparan sulfate in fibroblast growth factor signalling: a structural view

21 January 2018

1 reference

Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects

21 January 2018

1 reference

O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis.

21 January 2018

1 reference

Unraveling the specificity of heparanase utilizing synthetic substrates

21 January 2018

1 reference

The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site.

21 January 2018

1 reference

Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity

21 January 2018

1 reference

Viral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan Sulfate Interaction

21 January 2018

1 reference

The Importance of Heparan Sulfate in Herpesvirus Infection

21 January 2018

1 reference

Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis.

21 January 2018

1 reference

Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides

21 January 2018

1 reference

Entry inhibitors in the treatment of HIV-1 infection

21 January 2018

1 reference

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

21 January 2018

1 reference

Syndecans and HIV-1 pathogenesis

21 January 2018

1 reference

Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site.

21 January 2018

1 reference

HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection

21 January 2018

1 reference

Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins

21 January 2018

1 reference

A triad of lys12, lys41, arg78 spatial domain, a novel identified heparin binding site on tat protein, facilitates tat-driven cell adhesion

21 January 2018

1 reference

Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives

21 January 2018

1 reference

Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells

21 January 2018

1 reference

Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists

21 January 2018

1 reference

Focus on antivirally active sulfated polysaccharides: from structure-activity analysis to clinical evaluation.

21 January 2018

1 reference

Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate.

21 January 2018

1 reference

Structural features and anti-HIV-1 activity of novel polysaccharides from red algae Grateloupia longifolia and Grateloupia filicina

21 January 2018

1 reference

Inhibition of reverse transcriptase activity of HIV by polysaccharides of brown algae

21 January 2018

1 reference

The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1

21 January 2018

1 reference

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

21 January 2018

1 reference

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features

21 January 2018

1 reference

Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D

21 January 2018

1 reference

The multipartite system that mediates entry of herpes simplex virus into the cell

21 January 2018

1 reference

Soluble 3-O-sulfated heparan sulfate can trigger herpes simplex virus type 1 entry into resistant Chinese hamster ovary (CHO-K1) cells

21 January 2018

1 reference

Herpesvirus entry: an update

21 January 2018

1 reference

Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C.

21 January 2018

1 reference

Mutational analysis of the major heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C.

21 January 2018

1 reference

Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1.

21 January 2018

1 reference

Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host-cell interaction

21 January 2018

1 reference

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread

21 January 2018

1 reference

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial

21 January 2018

1 reference

Inhibition of herpes simplex virus types 1 and 2 in vitro infection by sulfated derivatives of Escherichia coli K5 polysaccharide

21 January 2018

1 reference

Biology of human papillomaviruses

21 January 2018

1 reference

alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP.

21 January 2018

1 reference

Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses

21 January 2018

1 reference

Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus

21 January 2018

1 reference

Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus.

21 January 2018

1 reference

Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus

21 January 2018

1 reference

Escherichia coli K5 heparosan fermentation and improvement by genetic engineering

21 January 2018

1 reference

Controlled release of 2, 3 desulfated heparin exerts its anti-inflammatory activity by effectively inhibiting E-selectin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.21263

1 reference

26 August 2017

1 reference